(Q44551301)

4 December 2017

Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion (English)

1 reference

4 December 2017

1 reference

1 reference

5

David P Nicolau

1 reference

4 December 2017

Prachi K Dandekar

1

1 reference

4 December 2017

Dana Maglio

series ordinal

2

1 reference

4 December 2017

Christina A Sutherland

series ordinal

3

1 reference

4 December 2017

Charles H Nightingale

series ordinal

4

1 reference

4 December 2017

language of work or name

English

0 references

publication date

1 August 2003

1 reference

4 December 2017

1 reference

4 December 2017

23

1 reference

4 December 2017

8

1 reference

4 December 2017

988-991

1 reference

Pharmacokinetics of high-dose meropenem in adult cystic fibrosis patients

4 December 2017

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.8.988.32878

Comparative pharmacokinetics of the carbapenems: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.8.988.32878

Meropenem clinical pharmacokinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.8.988.32878

MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: resistance implications in the treatment of serious infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.8.988.32878

A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.8.988.32878

10.1592/PHCO.23.8.988.32878

21 January 2018

Identifiers

DOI

1 reference

4 December 2017

1 reference